ABVC BioPharma, Inc. filings document the regulatory record of a Nevada clinical-stage biopharmaceutical company focused on ophthalmology, CNS, and oncology/hematology programs. The company’s disclosures include Form 8-K reports for financial results and material events, proxy materials for annual shareholder meetings, board elections, and shareholder voting results.
ABVC’s SEC filings also cover governance and capital-structure matters, including unregistered common stock sales under Regulation S, voting-rights proxy arrangements connected to those sales, director and officer compensation arrangements, changes in the company’s independent registered public accounting firm, and formal reporting around shareholder approvals and corporate controls.
ABVC BioPharma, Inc. reported continued operating losses and a strained liquidity position while advancing multiple clinical programs and licensing arrangements. For the periods shown, the company recorded net losses of $2.33 million and $3.28 million (two comparable periods), with net loss attributable to ABVC of $2.26 million and $3.10 million in the comparable reporting periods. Basic and diluted net loss per share ranged from $(0.08) to $(0.36) depending on period and share count. Current liabilities totaled $6.53 million with a working capital deficit near $(3.76) million. Cash flows show investing uses of $(665,779) and financing proceeds of $2.54 million in the reporting period. Long-term investments and prepayments total several million, and the company discloses substantial related-party loans and short-term borrowings. Clinical pipeline progress includes completed Phase II for ABV-1504 (MDD), ongoing Phase II Part 2 for ABV-1505 (ADHD), planned Phase I for ABV-1601, and initiated Phase II for ABV-1701 Vitargus (medical device). License/milestone schedule includes $1M for IND, $1M for Phase II completion, $3M for Phase III initiation, and $4M for NDA submission.
ABVC BioPharma reported a loss and continuing financing reliance. The filing shows significant operating losses and negative working capital while the company advances multiple clinical and device programs.
For the period presented, net loss attributable to ABVC was $2,257,022 for the quarter and $3,099,097 for the six-month period, with basic and diluted net loss per share of $(0.13) and $(0.19) for the comparable periods. Current liabilities totaled $6,532,514 producing a working capital deficit of $(3,762,113). Long-term investments were $2,837,922 and property and equipment, net was reported at $8,215,366. Cash flow from financing activities provided $2,536,083 while investing used $(665,779). The company disclosed related-party loans and short-term borrowings, loaned funds to affiliates (BioFirst) and a warrant exercise arrangement with Lind to raise equity proceeds. The business continues multiple clinical programs (ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, ABV-1703) and milestone-based license payments tied to IND, Phase II, Phase III and NDA events.
ABVC BioPharma, Inc. reported continued operating losses and negative working capital while advancing multiple clinical programs and relying on financing and related-party support. For the six months ended June 30, 2025 the company recorded a net loss of $2.332 million versus a loss of $1.047 million in the prior period. Basic and diluted net loss per share for the quarter/period presented include $(0.13) and (figures shown in the report). Total current liabilities were $6.533 million with a working capital deficit of $(3.762 million). Total assets included cash/current assets and long-term investments that aggregate to reported totals (long-term investments noted at $2.838 million). Cash flows show cash used in investing activities of $(665,779) and cash provided by financing activities of $2.536 million. The company discloses material related-party loans, convertible debt exercises and warrant exercises as financing sources and milestone payment schedules tied to development and licensing (e.g., IND/Phase II/III/NDA payments totaling up to $10 million under a development agreement). The filing lists multiple clinical assets (ABV-1504, ABV-1505, ABV-1601, ABV-1519, ABV-1701, ABV-1703) at various Phase I/II/II-part stages and strategic licensing objectives.
ABVC BioPharma reported continued operating losses and negative working capital as of June 30, 2025. Revenue was nil while operating expenses rose to $2.29 million for the quarter, producing a net loss of $2.33 million for the quarter and $3.28 million for the six months ended June 30, 2025. Cash flows from operations were negative while financing activities provided $2.54 million, partially offsetting investing outflows of $0.67 million. Current liabilities totaled $6.53 million producing a working capital deficit of $3.76 million. The company holds long-term investments of $2.84 million and prepayments for investments and asset acquisitions totaling about $1.82 million. Clinical-stage assets include multiple drugs and a medical device in Phase I/II or Phase II, with milestones and licensing payments outlined for IND, Phase II, Phase III and NDA events.
ABVC BioPharma reports continued development-stage operations with multiple clinical programs and material losses. The company recorded net losses attributable to ABVC and subsidiaries of $2,257,022 and $942,336 in presented periods, and basic and diluted net loss per share figures shown of $(0.13), $(0.08), $(0.19), and $(0.36) for the periods reported. Current liabilities were stated at $6,532,514 and $6,557,461, and working capital deficits of $(3,762,113) and $(4,377,616) were disclosed. Cash flow provided by financing activities increased to $2,536,083 from $1,726,303, while cash flow used in investing activities was $(665,779).
The filing highlights active R&D: completed Phase II for ABV-1504 (MDD), Phase II Part 1 for ABV-1505 (ADHD) with Part 2 ongoing, planned Phase I for ABV-1601, and ongoing device study ABV-1701 (Vitargus®) in Phase II. Contractual milestone structure for licensing includes aggregate milestone payments of $10 million staged across IND, Phase II, Phase III and NDA events.
ABVC BioPharma, Inc. filed a current report to let investors know it has released its financial results for the second quarter ended June 30, 2025. The company states that these results are presented in a press release dated August 14, 2025, which is included as Exhibit 99.1. This information is being furnished rather than filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced. The report also clarifies that neither the document nor its exhibits constitute an offer to sell or a solicitation to buy any of ABVC’s securities.
ABVC BioPharma received an amended Schedule 13G filed by Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton reporting beneficial ownership of 557,143 shares, equal to 3.2% of the outstanding common stock. The position is composed of 0 currently held common shares, 500,000 B Warrants and 57,143 shares issuable under convertible securities. Lind Global Partners II LLC and Mr. Easton report sole voting and dispositive power over the position.
The filing includes a certification that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.
ABVC BioPharma has filed a Form S-8 registration statement to register an additional 2,515,989 shares of common stock under its Second Amended and Restated 2016 Equity Incentive Plan. The company's authorized capital consists of 100 million shares of common stock and 20 million shares of preferred stock, both with $0.001 par value.
Key details:
- Currently has 16,773,261 shares of common stock outstanding
- No preferred stock currently outstanding
- Classified as a non-accelerated filer and smaller reporting company
- Led by CEO Dr. Uttam Patil, who also serves as Interim CFO
The filing includes comprehensive indemnification provisions for directors and officers under Nevada law (NRS 78.138), protecting them against liability except in cases of intentional misconduct, fraud, or knowing violations of law. The registration statement incorporates by reference various SEC filings from 2025, including annual, quarterly, and current reports.